NO20021475L - Vasopressinantagonist, formulering og fremgangsmåte - Google Patents

Vasopressinantagonist, formulering og fremgangsmåte

Info

Publication number
NO20021475L
NO20021475L NO20021475A NO20021475A NO20021475L NO 20021475 L NO20021475 L NO 20021475L NO 20021475 A NO20021475 A NO 20021475A NO 20021475 A NO20021475 A NO 20021475A NO 20021475 L NO20021475 L NO 20021475L
Authority
NO
Norway
Prior art keywords
component
formulation
pharmaceutically acceptable
vasopressin antagonist
formulations
Prior art date
Application number
NO20021475A
Other languages
English (en)
Other versions
NO20021475D0 (no
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20021475D0 publication Critical patent/NO20021475D0/no
Publication of NO20021475L publication Critical patent/NO20021475L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

Det er beskrevet nye formuleringer for N-[4-(5H-pyrrolo[2,1-c][1,4]benzo- diazepin-10(11H)ylkarbonyl)-3-klorfenyl]-5-fluor-2-metyl-benzamid eller et farmasøytisk akseptabelt salt derav, og fremgangsmåter for fremstilling av disse, idet formuleringene omfatter fra omtrent 1 % til omtrent 20 % aktiv ingrediens, fra omtrent 1 % til omtrent 18 % av en overflateaktiv middel- komponenet, fra omtrent 50 % til omtrent 80 % av en komponent av en eller flere polyetylenglykoler, fra omtrent 1 % til omtrent 20 % av en komponent av en eller flere sukrosefettsyrer og/eller polyvinylpyrrolidon, og eventuelt en eller flere farmasøytisk akseptable konserveringsmidler eller antioksydanter.
NO20021475A 1999-09-27 2002-03-25 Vasopressinantagonist, formulering og fremgangsmåte NO20021475L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27
PCT/US2000/026369 WO2001022945A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Publications (2)

Publication Number Publication Date
NO20021475D0 NO20021475D0 (no) 2002-03-25
NO20021475L true NO20021475L (no) 2002-04-16

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021475A NO20021475L (no) 1999-09-27 2002-03-25 Vasopressinantagonist, formulering og fremgangsmåte

Country Status (18)

Country Link
EP (1) EP1216033A1 (no)
JP (1) JP2003510269A (no)
KR (1) KR20020039354A (no)
CN (1) CN1391466A (no)
AR (1) AR025780A1 (no)
AU (1) AU7615000A (no)
BR (1) BR0014351A (no)
CA (1) CA2388474A1 (no)
CZ (1) CZ20021083A3 (no)
EA (1) EA200200414A1 (no)
HK (1) HK1045109A1 (no)
HU (1) HUP0202972A3 (no)
IL (1) IL148541A0 (no)
MX (1) MXPA02003189A (no)
NO (1) NO20021475L (no)
PL (1) PL354282A1 (no)
WO (1) WO2001022945A1 (no)
ZA (1) ZA200203312B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
MXPA02003189A (es) 2002-09-30
KR20020039354A (ko) 2002-05-25
IL148541A0 (en) 2002-09-12
EP1216033A1 (en) 2002-06-26
CZ20021083A3 (cs) 2002-06-12
HUP0202972A2 (hu) 2002-12-28
AR025780A1 (es) 2002-12-11
HUP0202972A3 (en) 2003-07-28
ZA200203312B (en) 2003-12-31
WO2001022945A1 (en) 2001-04-05
CA2388474A1 (en) 2001-04-05
CN1391466A (zh) 2003-01-15
EA200200414A1 (ru) 2002-12-26
NO20021475D0 (no) 2002-03-25
HK1045109A1 (zh) 2002-11-15
BR0014351A (pt) 2002-06-11
PL354282A1 (en) 2003-12-29
AU7615000A (en) 2001-04-30
JP2003510269A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
NZ511903A (en) Use of alpha-keto enamine derivatives as ingredients
NZ506989A (en) Fizzy formulations for an alkali sensitive active agents containing organic edible acid and an alkaline earth carbonate
ATE215359T2 (de) Aerosolformulierungen
YU39800A (sh) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
HRP20020182B1 (en) Benzamide formulation with histone deacetylase inhibitor activity
RS52548B (en) ORAL DOSAGE FORM CONTAINED BY PDE 4 INHIBITOR AS ACTIVE INGREDIENT AND POLYVINYL PYRILIDONE AS EXPIENT
MY127749A (en) Liquid formulation
CA2360300A1 (en) A transdermal composition of an antivomiting agent and a preparation containing the same
NO20021475L (no) Vasopressinantagonist, formulering og fremgangsmåte
ATE253359T1 (de) Antithrombotische mittel
WO2001022969A3 (en) Vasopressin agonist formulation and process
DE69828522D1 (de) Antithrombotische mittel
NO20021476L (no) Farmasöytisk b¶rerformulering
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
EP0056681A3 (en) Levonantradol and n-methyllevonantradol formulations
NZ521515A (en) Composition comprising paracetamol and niflumic acid
DE69824410D1 (en) Antithrombosemittel
UY28095A1 (es) Composición farmacéutica
AU1434201A (en) Antithrombotic agents
MY116032A (en) Liquid composition comprising an hiv protease inhibitor and a, c12-c18 fatty acid
MX9702532A (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
JO1664B1 (en) The compound has the effect of immobilizing gastric acid and the process of preparing it

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application